
Takeda Pharmaceutical Company Limited (TAK) – Riding high on global expansion strategy
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on September 9, 2022This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.
Takeda Pharmaceutical Company Limited (TAK)
Takeda is also one of the attractive option for the investor, due to its effective cash management strategies. The Tokyo based organization knows how to deploy its cash in a manner which leads to growth and add value to the shareholders.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
No of Pages : 31